UCSF and BridgeBio to Develop New Therapies
BridgeBio is building close relationships with UCSF investigators to bring potential therapies into the clinic quickly.
Read More
Autobahn Collaboration to Accelerate UCSF Innovation
UCSF's Strategic Alliances team launched a new collaboration with Autobahn Labs, to help move novel therapeutics more quickly to market.
More
An Interview: Leadership in a  Post Pandemic Landscape
"We're not here to turn researchers into entrepreneurs – we are here to let the researcher understand what it is, and then participate however they like."
Read
UCSF Startup and Bio-Me to Collaborate
UCSF startup Siolta Therapeutics, founded by Professor Susan Lynch, and Bio-Me aim to develop a predictive test for infants to determine microbiome-based pediatric allergies.
More
Nobel Prize for CRISPR
UCSF Innovation Ventures congratulates Jennifer Doudna on her Nobel Prize in chemistry for her work in the development of CRISPR, a revolutionary gene-editing tool. May this honor boost Doudna's collaboration with UCSF at our Lab For Genetic Research.
MORE
Digital Health Awards 2020
And the winners are...
more
Congratulations to Digital Health
UCSF Innovation Ventures congratulates all the healthcare companies that submitted to the digital health awards. It is your great work that advances healthcare for all.
Watch
Gilead to Acquire a Nearly 50% Interest in UCSF Startup
Gilead Sciences set to acquire a 49.9% equity interest in Max Krummel's Pionyr Immunotherapeutics for $275 Million.
More
FDA Approves UCSF ADHD Therapy for Kids
FDA approves technology based on UCSF neurology professor Adam Gazzaley, that is used in the form of a kids video game to help children suffering from ADHD learn to focus.
MORE
Pliant Therapeutics Goes Public
Pliant Therapeutics, founded on UCSF's Drs. Dean Sheppard and William DeGrado's technology to develop therapies for the treatment of fibrosis, successfully filed their initial public offering with the FDC.
More
RAN Collaboration Enters Round 2.0
The RAN consortium comprising research groups including UCSF, the University of Chicago and the University of Toronto have entered into a second research collaboration with Bristol Myers Squibb.
More
Citizen Science Study to Help Fight COVID-19
Using the Eureka Mobile Research Platform, UCSF has launched a world-wide study to track COVID-19 symptoms, infections, risk factors and behaviors that might impact spread.
Read More

Who We Are

Translational technology development and commercialization is a complex process because every project is unique. Innovation Ventures is dedicated to helping the UCSF community navigate those complexities by working up-close with our research faculty and promising students to really understand their science. We have a single purpose and that is to support the transition of UCSF innovation out of the lab and into the marketplace as more fully developed therapies, with a greater confidence of success. Whether evaluating a new discovery, securing funding, seeking external partnerships, or starting new companies, Innovation Ventures is here to facilitate protection, development, and commercialization of novel and valuable healing inventions.

From Innovation...

...to Impact